Physician profile
Maury Buchalter
NPI 1700842093
$6,352.92
in general payments reported to CMS, 2019-2025
11 companies · $270 in 2025
The $270 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,178 · 2020: $39.97 · 2021: $122 · 2022: $240 · 2023: $216 · 2024: $287 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $5,226.72 | 2019-2025 | Bexsero |
| Kaleo, INC. | $229.91 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $176.40 | 2019-2024 | |
| Cranial Technologies, INC | $136.63 | 2019-2024 | Doc Band |
| Galderma Laboratories, L.P. | $128.16 | 2019 | |
| Merck Sharp & Dohme LLC | $116.05 | 2019-2023 | Vaxelis, Gardasil 9, Rotateq |
| Ars Pharmaceuticals Operations, INC. | $115.07 | 2025 | Neffy |
| Sanofi Pasteur INC. | $93.29 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $89.52 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.17 | 2023 | |
| Seqirus USA INC | $19.00 | 2025 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maury Buchalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.